On Wednesday, KalVista Pharmaceuticals stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 82, up from 79 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily identifies share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
History reveals that the market's biggest winners typically have an 80 or better RS Rating in the early stages of their moves.
Is KalVista Pharmaceuticals Stock A Buy?
KalVista Pharmaceuticals stock barely reclaimed its 50-day moving line on Wednesday and is currently not in a buying range. See if the biotech stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The biotech company posted 0% earnings growth in its most recent report, while sales growth came in at 0%. The company is expected to report its latest results on or around Sep. 4.
KalVista Pharmaceuticals stock earns the No. 231 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
